BDSX vs VCYT
BDSX: Biodesix develops precision diagnostic tests powered by molecular and AI analysis to guide oncology treatment decisions for clinicians, payers, and biopharmaceutical companies. VCYT: Veracyte is a genomics-focused diagnostics company providing high-value clinical tests to improve cancer detection and treatment guidance for patients worldwide.
Side-by-side fundamentals
| Metric | BDSX | VCYT | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $22.22 | $59.78 | |
| Market cap as of 2026-07-31 | $221M | $4.8B | |
| P/E as of 2026-07-31 | n/a | 55.37 | |
| PEG as of 2026-07-31 | n/a | 0.32 | |
| Net margin as of 2026-07-31 | -33.3% | +16.3% | VCYT higher |
| Gross margin as of 2026-07-31 | +82.1% | +70.9% | BDSX higher |
| Operating margin as of 2026-07-31 | -25.9% | +15.1% | VCYT higher |
| ROE as of 2026-07-31 | -375.1% | +6.9% | VCYT higher |
| ROA as of 2026-07-31 | -35.6% | +6.3% | VCYT higher |
| Debt / equity as of 2026-07-31 | 5.09 | 0.00 | VCYT lower |
| Revenue growth (YoY) as of 2026-07-31 | +29.1% | +16.9% | BDSX higher |
| Revenue CAGR (3y) SEC XBRL | +32.3% | +20.4% | BDSX higher |
| Beta as of 2026-07-31 | 0.59 | 1.39 | |
| 1-year return as of 2026-07-27 close | +149.1% | +149.4% | VCYT higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.